Investigating the link between the atheronals and aging
研究动脉粥样硬化与衰老之间的联系
基本信息
- 批准号:7124089
- 负责人:
- 金额:$ 22.87万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-08-15 至 2008-06-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): This proposal, submitted in response to RFA-AG-05-011, explores the age-related changes of the newly discovered inflammation-derived lipidic aldehydes, atheronal-A and -B. We have recently shown that the atheronals are present in vivo within human atherosclerotic plaque material, plasma and brain tissue. Critically, we have shown that the levels of the atheronals within inflamed arteries are significantly elevated upon leukocyte activation. Furthermore we have shown in vitro that the atheronals have biological effects that make them inflammatory mediators. Furthermore we have shown that the atheronals accelerate the misfolding and aggregation of the neurotoxic beta-amyloid peptide. Atheronals have a plasma half-life in mice of several minutes, are freely diffusible between cells and fluid compartments and can thus can impact distant anatomic sites away from the active location of inflammation. Thus, as byproducts of the chronic inflammation that characterizes atherosclerosis within the vascular endothelium, the atheronals may serve as antagonistic chemical mediators of late life disease, both atherosclerosis progression and Alzheimer's disease (AD). We hypothesize therefore that the atheronals, as inflammatory mediators, may be a chemical link that explains the known epidemiologic convergence between atherosclerosis and AD, two major diseases of aging, and may also serve as an example of how ageing within one organ system can affect another. This R21 proposal outlines research in animal systems to quantify the effect of ageing on atheronal levels, and whether atheronal exposure in early life can impact later life pathophysiological changes. This proposal will investigate the relationships of age-related changes in atheronal levels to physiologic and pathophysiologic ageing changes in organ function by investigating the following three specific aims:
1) Specific aim #1 Determine the effect of age and atherosclerosis progression on plasma and vascular tissue levels of the atheronals in two murine models of atherosclerosis, the Apo-E deficient (ApoE-/-) and LDLreceptor deficient (LDL-/-) mouse strains. 2) Specific aim #2 Determine the effect of age and atherosclerosis progression on brain tissue levels of the atheronals in the , ApoE-/- and LDL-/- murine models of atherosclerosis. 3) Specific aim # 3 Determine if early age exposure to atheronals results in an increased severity of the late life ageing disorders of atherosclerosis and Alzheimer's disease in murine models of atherosclerosis, ApoE-/- and LDL-/- and a human APP transgenic mouse model (Jackson labs).
描述(由申请人提供):本提案是为响应RFA-AG-05-011而提交的,旨在探索新发现的炎症源性雌二醇(atheronal-A和B)的年龄相关变化。我们最近发现动脉粥样硬化存在于人体动脉粥样硬化斑块物质、血浆和脑组织中。重要的是,我们已经表明,炎症动脉内的动脉粥样硬化水平在白细胞活化后显著升高。此外,我们已经在体外证明动脉粥样硬化具有生物学效应,使其成为炎症介质。此外,我们已经表明,动脉粥样硬化加速神经毒性β-淀粉样肽的错误折叠和聚集。动脉粥样硬化剂在小鼠中的血浆半衰期为几分钟,可在细胞和流体隔室之间自由扩散,因此可影响远离炎症活动部位的远距离解剖部位。因此,作为表征血管内皮内的动脉粥样硬化的慢性炎症的副产物,动脉粥样硬化剂可以充当晚年疾病(动脉粥样硬化进展和阿尔茨海默病(AD))的拮抗性化学介质。因此,我们假设动脉粥样硬化,作为炎症介质,可能是一种化学联系,解释了动脉粥样硬化和AD,两种主要的衰老疾病之间的流行病学收敛,也可以作为一个例子,一个器官系统内的衰老如何影响另一个。这一R21提案概述了动物系统的研究,以量化衰老对动脉粥样硬化水平的影响,以及早期生命中的动脉粥样硬化暴露是否会影响晚年的病理生理变化。本提案将通过调查以下三个具体目标,调查动脉粥样硬化水平的年龄相关变化与器官功能的生理和病理生理老化变化之间的关系:
1)具体目标#1确定年龄和动脉粥样硬化进展对两种动脉粥样硬化小鼠模型(Apo-E缺陷(ApoE-/-)和LDL受体缺陷(LDL-/-)小鼠品系)中动脉粥样硬化的血浆和血管组织水平的影响。2)具体目标#2确定年龄和动脉粥样硬化进展对ApoE-/-和LDL-/-动脉粥样硬化小鼠模型中动脉粥样硬化脑组织水平的影响。3)具体目标#3在动脉粥样硬化的鼠模型、ApoE-/-和LDL-/-以及人APP转基因小鼠模型(杰克逊实验室)中确定早期暴露于动脉粥样硬化是否导致动脉粥样硬化和阿尔茨海默病的晚年衰老障碍的严重程度增加。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PAUL WENTWORTH其他文献
PAUL WENTWORTH的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PAUL WENTWORTH', 18)}}的其他基金
C3 Tumor Associated Carbohydrate Antigen Bioconjugates
C3 肿瘤相关碳水化合物抗原生物缀合物
- 批准号:
8424948 - 财政年份:2012
- 资助金额:
$ 22.87万 - 项目类别:
C3 Tumor Associated Carbohydrate Antigen Bioconjugates
C3 肿瘤相关碳水化合物抗原生物缀合物
- 批准号:
8301502 - 财政年份:2012
- 资助金额:
$ 22.87万 - 项目类别:
C3 chemical conjugation to improve the anti-cocaine immune response
C3化学缀合改善抗可卡因免疫反应
- 批准号:
8233313 - 财政年份:2011
- 资助金额:
$ 22.87万 - 项目类别:
C3 chemical conjugation to improve the anti-cocaine immune response
C3化学缀合改善抗可卡因免疫反应
- 批准号:
8092919 - 财政年份:2011
- 资助金额:
$ 22.87万 - 项目类别:
Lactobacilli surface antibody expression for in vivo protection against cholera
乳酸杆菌表面抗体表达可体内预防霍乱
- 批准号:
7772625 - 财政年份:2010
- 资助金额:
$ 22.87万 - 项目类别:
Lactobacilli surface antibody expression for in vivo protection against cholera
乳酸杆菌表面抗体表达可体内预防霍乱
- 批准号:
8033092 - 财政年份:2010
- 资助金额:
$ 22.87万 - 项目类别:
Beauveriolide-Derived Cyclodepsipeptides as a New Class of Anti-Alzheimer's Drugs
Beauveriolide 衍生的环缩酚肽作为一类新型抗阿尔茨海默病药物
- 批准号:
7758245 - 财政年份:2009
- 资助金额:
$ 22.87万 - 项目类别:
Antibody Generation of ROS and Macular Degeneration
ROS 和黄斑变性的抗体生成
- 批准号:
7273892 - 财政年份:2006
- 资助金额:
$ 22.87万 - 项目类别:
Investigating the link between the atheronals and aging
研究动脉粥样硬化与衰老之间的联系
- 批准号:
7273894 - 财政年份:2006
- 资助金额:
$ 22.87万 - 项目类别:
Antibody Generation of ROS and Macular Degeneration
ROS 和黄斑变性的抗体生成
- 批准号:
7096710 - 财政年份:2006
- 资助金额:
$ 22.87万 - 项目类别:
相似国自然基金
新型F-18标记香豆素衍生物PET探针的研制及靶向Alzheimer's Disease 斑块显像研究
- 批准号:81000622
- 批准年份:2010
- 资助金额:20.0 万元
- 项目类别:青年科学基金项目
阿尔茨海默病(Alzheimer's disease,AD)动物模型构建的分子机理研究
- 批准号:31060293
- 批准年份:2010
- 资助金额:26.0 万元
- 项目类别:地区科学基金项目
跨膜转运蛋白21(TMP21)对引起阿尔茨海默病(Alzheimer'S Disease)的γ分泌酶的作用研究
- 批准号:30960334
- 批准年份:2009
- 资助金额:22.0 万元
- 项目类别:地区科学基金项目
相似海外基金
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10531959 - 财政年份:2022
- 资助金额:
$ 22.87万 - 项目类别:
The Role of Menopause-Driven DNA Damage and Epigenetic Dysregulation in Alzheimer s Disease
更年期驱动的 DNA 损伤和表观遗传失调在阿尔茨海默病中的作用
- 批准号:
10700991 - 财政年份:2022
- 资助金额:
$ 22.87万 - 项目类别:
Oligodendrocyte heterogeneity in Alzheimer' s disease
阿尔茨海默病中的少突胶质细胞异质性
- 批准号:
10180000 - 财政年份:2021
- 资助金额:
$ 22.87万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10049426 - 财政年份:2021
- 资助金额:
$ 22.87万 - 项目类别:
Repurposing drugs for Alzheimer´s disease using a reverse translational approach
使用逆翻译方法重新利用治疗阿尔茨海默病的药物
- 批准号:
10295809 - 财政年份:2021
- 资助金额:
$ 22.87万 - 项目类别:
Serum proteome analysis of Alzheimer´s disease in a population-based longitudinal cohort study - the AGES Reykjavik study
基于人群的纵向队列研究中阿尔茨海默病的血清蛋白质组分析 - AGES 雷克雅未克研究
- 批准号:
10390278 - 财政年份:2021
- 资助金额:
$ 22.87万 - 项目类别:
Evaluating the role of the caregiver in the quality of life of people with Parkinson?s disease: opportunities for intervention
评估护理人员在帕金森病患者生活质量中的作用:干预机会
- 批准号:
10088327 - 财政年份:2020
- 资助金额:
$ 22.87万 - 项目类别:
Evaluating the role of the caregiver in the quality of life of people with Parkinson?s disease: opportunities for intervention
评估护理人员在帕金森病患者生活质量中的作用:干预机会
- 批准号:
9907351 - 财政年份:2020
- 资助金额:
$ 22.87万 - 项目类别:
Dementia and hearing loss: Using preclinical models to uncover the mechanisms that accelerate cognitive decline in Alzheimer?s disease
痴呆和听力损失:利用临床前模型揭示加速阿尔茨海默病认知能力下降的机制
- 批准号:
429089 - 财政年份:2019
- 资助金额:
$ 22.87万 - 项目类别:
Studentship Programs
Thalamic Contributions to Functional Network Abnormalities in Alzheimer''s Disease
丘脑对阿尔茨海默病功能网络异常的贡献
- 批准号:
10415553 - 财政年份:2019
- 资助金额:
$ 22.87万 - 项目类别: